Publications by authors named "Javier Gonzalez Polo"
Curr Med Res Opin
August 2024
Article Synopsis
- MSB11022 is a biosimilar to adalimumab that has shown comparable effectiveness and safety in patients with rheumatoid arthritis (RA) who switched from the reference adalimumab or another biosimilar.
- *This study was a retrospective, multicenter analysis of 86 RA patients who maintained treatment with MSB11022 for at least 6 months, revealing high rates of disease remission and low activity.
- *The results indicated that MSB11022 preserves the treatment benefits of adalimumab, with minimal adverse effects reported, consistent with existing safety profiles of other biosimilars.*
